Tobacco usage is the single most preventable cause of mortality and morbidity in our society today. It is responsible for more than 430,000 deaths per year in the United States alone. Smoking is a causative factor in numerous fatal and nonfatal diseases, including heart disease, chronic obstructive pulmonary disease, and several types of cancer (eg, lung, larynx, bladder, pancreatic, oral, esophageal, stomach, and kidney cancers).
The role of cigarette smoking in causing cancer is not surprising since among the more than 4,000 constituents of tobacco are over 40 known carcinogens. In fact, smoking is responsible for 30.5% of all cancer deaths. In males alone, it accounts for 89% of lung cancer deaths, 90% of oral cancer deaths, 76.7% of esophageal cancer deaths, 79.3% of laryngeal cancer deaths, and 44.6% of kidney cancer deaths.
Smoking-related cancer mortality statistics are similar among women, and in fact, lung cancer has recently surpassed breast cancer as the leading cause of death among women. In addition, 30.8% of cervical cancer deaths are attributable to female cigarette smoking. In all, 23% of cancer deaths among women and 42% among men are due to smoking tobacco products.
Smoking may increase ones risk of cancer, but quitting smoking results in a decline in ones risk of developing malignancy and may even increase survival time in those already affected. Depending on the number of years of abstinence, the risk of developing lung cancer decreases by 20% to 90% when one quits smoking. The risk of developing oral cancer is cut in half after only 3 to 5 years and, after 10 years of abstinence, returns to that of a person who has never smoked.
Given statistics such as these, it is easy to understand the need for smoking cessation treatment and the importance of integrating this service into primary medical care, cancer prevention, and oncologic treatment. The goal of this paper is to review current trends in behavioral and pharmacologic approaches to smoking cessation. These include standard treatment methods, such as behavioral counseling and nicotine replacement, as well as adjunctive therapies that are under preliminary investigation.
Although smoking prevalence has decreased dramatically over the past 25 years, the number of people who currently smoke is still substantial. At present, one-fourth (25.5%) of adult Americans, or about 48 million people, smoke. Most of these individuals reportedly want to quit but have great difficulty in doing so. Data from the 1994 National Health Interview Supplement (NHIS-2000) indicated that nearly 70% of smokers want to stop smoking completely and 46.4% had made a serious quit attempt (quitting for at least 1 day) in the year prior to the survey. Testifying to the difficulty of this action, however, only 5.7% of smokers successfully abstained from smoking for at least 1 month and an estimated 2.5% of all smokers quit permanently each year.
Unassisted Quitting and Self-Help Interventions
The small percentage of successful quitters each year probably reflects the fact that most smokers prefer to quit on their own using such methods of quitting as cold turkey, gradual reduction, or some other self-help approach. Only 15% of smokers report using assisted or more intensive treatments (eg, physicians advice, counseling, and nicotine replacement).
Self-help modalities have not generally been proven effective, however. In fact, in a prospective, multicenter study of 5,000 smokers, only 4.3% of self-quitters remained abstinent 1 year after their cessation attempt. A panel of experts convened by the Agency for Health Care Policy and Research (AHCPR) to review the smoking cessation literature and establish clinical practice guidelines concluded that written materials do not increase abstinence rates relative to no intervention at all.
Although other self-help modalities may be more promising, they still require further investigation. For example, slight increases in cessation rates have been noted when telephone counseling hot lines are used for smoker-initiated calls. In addition, the effectiveness of self-help materials appears to be increased by tailoring information to an individuals readiness to quit or specific barriers to cessation.[11-13] At present, it appears that the tailored self-help approaches may be of most benefit to smokers who are in the precontemplation stage of quitting, have low perceived ability to quit, or are less nicotine dependent.
Self-help interventions are attractive in that they are easy to disseminate, are low in cost, and are preferred by the general public. Therefore, further efforts to improve their efficacy are warranted. In their present form, however, self-help materials and unassisted cessation efforts do not significantly enhance quit attempts. More intensive treatment, including behavioral counseling, nicotine replacement, or the combination of the two, is required.
Assisted Smoking Cessation Treatments
The AHCPR recently published a comprehensive review of the empirical smoking cessation literature. A panel of experts in the field of smoking cessation was convened to evaluate the existing literature and make recommendations regarding efficacious cessation treatments. More than 300 controlled studies were reviewed. The results of this meta-analysis delineated three effective components of smoking cessation treatment: nicotine replacement therapy (patch or gum), social support (clinician-provided encouragement and assistance), and problem-solving/skills training (focusing on achieving and maintaining abstinence). Furthermore, the panels findings supported the combined use of behavioral intervention and nicotine replacement as the most effective intervention. Each of these treatments will be reviewed below.
Although there were insufficient data for the review panel to make any recommendations regarding the use of nonnicotine medications (eg, nicotine antagonists, antidepressants, and anxiolytics) in smoking cessation, a number of these medications have been investigated and will be reviewed here as well. Table 1 summarizes the major findings of the AHCPR panel and their recommendations for all health care providers.
Interventions that offer person-to-person contact (ie, group or individual counseling) provide a substantial treatment advantage over unassisted interventions. As shown in Table 2, in comparison to self-help interventions, the more time providers spend (intensity level) with smokers in a treatment session, the higher the likelihood of cessation. In the AHCPRs review, the highest cessation rates were observed for provider counseling sessions lasting longer than 10 minutes, but brief contact lasting 3 to 10 minutes and even minimal contact lasting less than 3 minutes improved a smokers chance of success over that of controls.
In addition, both the duration of treatment in weeks and the total number of treatment sessions improved the odds of cessation, even after controlling for treatment intensity (length of session). Significant improvements in cessation were observed for interventions involving four to seven sessions implemented over a period of 8 or more weeks.
In addition to looking at treatment intensity and duration, the AHCPR panel evaluated the efficacy of various treatment components. Among the components examined were: aversive (rapid) smoking, setting a quit day, counseling for diet or motivation for exercise, contingency contracting, relaxation, cigarette (brand) fading, intra- or extratreatment social support, and problem- solving/skills training. The results indicated that cessation counseling involving either general problem-solving/skills training (eg, relapse prevention, stress management) and/or supportive care provided by the clinician in the treatment session significantly improved cessation rates over no-contact controls.
Scheduled smoking is a unique behavioral approach that gradually weans smokers from their physiologic dependence on nicotine without concomitant nicotine replacement. Smokers are instructed to smoke on a fixed time schedule (eg, one cigarette at the beginning of every hour) with gradually increasing intercigarette intervals. In this way, individuals receive a steady, although declining, dosage of nicotine independent of environmental cues to smoke. This approach may be especially appropriate with special populations, such as individuals with medical conditions that preclude use of nicotine replacement therapy (eg, cardiac patients, presurgical patients, pregnant smokers) or individuals who are unwilling to use nicotine replacement therapy.
Scheduled smoking has been shown to be more effective than either uncontrolled gradual reduction or abrupt (cold turkey) cessation when each was combined with a relapse prevention program. One-year abstinence rates using scheduled smoking ranged from 32% to 44%, which compare favorably to those reported for psychological treatment combined with transdermal nicotine replacement (28% to 38%).[14,15]
1. USDHHS: The Health Benefits of Smoking Cessation: A Report of the Surgeon General. DHHS pub. no. (CDC) 90-8416. Washington, DC, Public Health Service, Centers for Disease Control, Center for Health Promotion and Education, Office on Smoking and Health, 1990.
2. CDC: Cigarette smoking-attributable mortality and years of potential life lost: United States, 1990. Morbid Mortal Weekly Rep 42:854-857, 1993.
3. USDHHS: Cancer: Rates and Risks, 4th ed. NIH (NCI) publication no. 96-691. Washington, DC, US Department of Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, 1996.
4. Newcombe PA, Carbone PP: The health consequences of smoking: Cancer. Med Clin North Am 76:305-331, 1992.
5. Samet JM: The health benefits of smoking cessation. Med Clin North Am 76:399-414, 1992.
6. CDC: Cigarette smoking among adultsUnited States, 1994. Morbid Mortal Weekly Rep 45:588-590, 1996.
7. CDC: Smoking cessation during previous year among adultsUnited States 1990 & 1991. Morbid Mortal Weekly Rep 42:504-507, 1993.
8. Fiore MC, Novotony TE, Pierce JP, et al: Methods used to quit smoking in the United States. JAMA 263:2760-2765, 1990.
9. Cohen S, Lichtenstein E, Prochaska JO: Debunking myths about self-quitting: Evidence from ten prospective studies of persons quitting smoking by themselves. Am Psychol 44:1955-1965, 1989.
10. Fiore MC, Bailey WC, Cohen SJ, et al: Smoking Cessation. Clinical Practice Guideline no. 18, AHCPR publication no. 96-0692. Rockville, Maryland, US Department of Health and Human Service, Agency for Health Care Policy and Research, April 1996.
11. Prochaska JO, DiClemente CC, Velicer WF, et al: Standardized, individualized, interactive, and personalized self-help programs for smoking cessation. Health Psychol 12:399-405, 1993.
12. Schneider SJ, Schwartz MD, Fast J: Computerized, telephone-based health promotion: I. Smoking cessation program. Comput Hum Behav 1:135-148, 1995.
13. Strecher VJ, Kreuter M, Den Boer D-J, et al: The effects of computer-tailored smoking cessation messages in family practice settings. J Fam Pract 39:262-270, 1994.
14. Cinciripini PM, Lapitsky L, Scay S, et al: The effects of smoking schedules on cessation outcome: Can we improve on common methods of gradual and abrupt nicotine withdrawal? J Consult Clin Psychol 63:388-399, 1995.
15. Cinciripini PM: Current trends in smoking cessation research: Psychological therapy, nicotine replacement, and changes in smoking behavior. Cancer Bull 47:259-263, 1995.
16. Hughes JR: Combining behavioral therapy and pharmacotherapy for smoking cessation: An update, in Onken LS, Blaine JD, Boren JJ, (eds): Integrating NIDA Research. Monograph 92-109. Washington, DC, US Government Printing Office, 1995.
17. Cepeda-Benito A: A meta-analytic review of the efficacy of nicotine chewing gum in smoking cessation treatment programs. J Consult Clin Psychol 61:822-30, 1993.
18. Silagy C, Mant D, Fowler G, et al: Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 343:139-142, 1994.
19. Tang JI, Law M, Wald N: How effective is nicotine replacement therapy in helping people to stop smoking? Br Med J 308:21-26, 1994.
20. Fiore MC, Smith SS, Jorenby DE, et al: The effectiveness of the nicotine patch for smoking cessation: A meta-analysis. JAMA 271:1940-1947, 1994.
21. Gourlay S: The pros and cons of transdermal nicotine therapy. Med J Aust 160:152-159, 1994.
22. Po ALW: Transdermal nicotine in smoking cessation: A meta-analysis. Eur J Clin Pharmacol 45:519-28, 1993.
23. Pierce JP, Gilpin E, Farkas Al: Nicotine patch use in the general population: Results from the 1993 California tobacco survey. J Natl Cancer Inst 87:87-93, 1995.
24. Willey C, Laforge R, Prochaska J, et al: Transdermal nicotine usage in a randomly selected population based sample of smokers. Ann Behav Med 17:S069, 1995.
25. Orleans CT, Resch N, Noll E, et al: Use of transdermal nicotine in a state-level prescription plan for the elderly. JAMA 271:601-607, 1994.
26. Kornitzer M, Boutsen M, Draxaix M, et al: Combined use of nicotine patch and gum in smoking cessation: A placebo-controlled clinical trial. Prev Med 24:4147, 1995.
27. Puska P, Korhonen J, Vartialnen E, et al: Combined use of the nicotine patch and gum compared with gum aline in smoking cessation: A clinical trial in North Karelia. Tob Control 4:231-235, 1995.
28. Schneider NG, Lunell E, Olmstead RE, et al: Clinical pharmacokinetics of nasal nicotine deliveryA review and comparison of other nicotine systems. Clin Pharmacokinet 31:65-80, 1996.
29. Schneider NG, Olmstead R, Mody FV, et al: Efficacy of a nicotine nasal spray in smoking cessationA placebo-controlled double-blind trial. Addiction 90:1671-1682, 1995.
30. Tonnesen P, Mikkelsen K, Norregaard J, et al: Recycling of hard-core smokers with nicotine nasal spray. Eur Respir J 9:1619-1623, 1996.
31. Schneider NG, Olmstead R, Freny Vaghaiwalla M, et al: Nicotine inhaler in smoking cessation: A double-blind, placebo-controlled trial. Presented at the Second Annual Conference for the Society for Research on Nicotine and Tobacco, Washington, DC, 1996.
32. Hughes JR: Non-nicotine pharmacotherapies for smoking cessation. J Drug Dev 6:197-203, 1994.
33. Clarke PBS: Nicotinic receptor blockade therapy and smoking cessation. Br J Addict 86:501-555, 1991.
34. Collins AC, Evans CB, Miner LL, et al: Mecamylamine blockade of nicotine responses: evidence for two brain nicotinic receptors. Pharmacol Biochem Behav 24:1767-1773, 1986.
35. Stolerman IP: Could nicotine antagonists be used in smoking cessation? Br J Addict 81:47-53, 1986.
36. Rose JE, Sampson A, Levin ED, et al: Mecamylamine increases nicotine preference and attenuates nicotine discrimination. Pharmacol Biochem Behav 32:933-938, 1989.
37. Nemeth-Coslett R, Henningfield JE, OKeeffe MK, et al: Effects of mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology (Berl) 88:420-425, 1986.
38. Stolerman P, Goldfarb T, Fink R, et al: Influencing cigarette smoking with nicotine antagonists. Psychopharmacology (Berl) 28:27-59, 1973.
39. Rose JE, Behm FM, Westman EC, et al: Mecamylarnine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Trials Ther 56: 86-99, 1994.
40. Gourlay SG, Benowitz NL: Is clonidine effective smoking cessation therapy? Drugs 50:197-207, 1995.
41. Niaura R, Brown RA, Goldstein MG, et al: Transdermal clonidine for smoking cessation: A double-blind randomized dose-response study. Exp Clin Psychopharmacol 4:285-291, 1996.
42. Jann MW: Buspirone: An update on a unique anxiolytic agent. Pharmacotherapy 8:100-116, 1988.
43. Taylor DP, Moon SL: Buspirone and related compounds as alternative anxiolytics. Neuropeptides 19:15-9, 1991.
44. Eison AS, Temple DL: Buspirone: A review of its pharmacology, current perspectives on its mechanism of action. Am J Med 80:1-9, 1986.
45. Robinson MD, Smith WA, Cederstrom EA, et al: Buspirone effect on tobacco withdrawal symptoms: A pilot study. J Am Board Fam Pract 4:89-94, 1991.
46. Robinson MD, Pettice YL, Smith WA: Buspirone effect on tobacco withdrawal symptoms: A randomized placebo-controlled trial. J Am Board Fam Pract 5:1-9, 1992.
47. West R, Hajek P, McNeill A: Effect of buspirone on cigarette withdrawal symptoms and short-term abstinence rates in a smokers clinic. Psychopharmacology(Berl) 104:91-96, 1991.
48. Hilleman DE, Mohiuddin SM, Delcore MG, et al: Effect of buspirone on withdrawal symptoms associated with smoking cessation. Arch Intern Med 152:350-352, 1992.
49. Cinciripini PM, Lapitsky L, Seay S, et al: A placebo-controlled evaluation of the effects of buspirone on smoking cessation: Differences between high- and low-anxiety smokers. J Clin Psychopharmacol 15:182-191, 1995.
50. Schneider NG, Olmstead RE, Steinberg C, et al: Efficacy of buspirone in smoking cessation: A placebo-controlled trial. Clin Pharmacol Ther 60:568-575, 1996.
51. Fowler JS, Volkow ND, Wang GJ, et al: Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 93:14065-14069, 1996.
52. Berlin I, Said S, Spreux-Varoquaux 0, et al: A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Trial Ther 58:444-452, 1995.
53. Niaura R, Goldstein M, Spring B, et al: Fluoxetine for smoking cessation: A multicenter randomized double blind dose response study. Ann Behav Med 19:S042, 1997.
54. Spring B, Wurtman J, el-Khoury A, et al: Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. Am J Clin Nutr 62:1181-1187, 1995.
55. Doherty K, Militello FS, Kinnunen T, et al: Nicotine gum dose and weight gain after smoking cessation. J Consult Clin Psychol 64:799-807, 1996.
56. Nides M, Rand C, Dolce J, et al: Weight gain as a function of smoking cessation and 2-mg nicotine gum use among middle-aged smokers with mild lung impairment in the first 2 years of the lung health study. Health Psychol 13:354-361, 1994.
57. Hurt RD, Sachs DPL, Glover ED, et al: A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195-1203, 1997.
58. Hall SM: New directions in medications for the treatment of tobacco dependence. Presented at the Society for Reasearch on Nicotine and Tobacco, Washington, DC, 1996.
59. Cinciripini P, Tsoh J, Friedman K, et al: A placebo controlled evaluation of venlafaxine for smoking cessation: Preliminary findings. Soc Res Nic Tob, 1997